Frederik Bartels1, Katharina Nobis2, Graham Cooper3, Eva Wendel4, Robert Cleaveland2, Barbara Bajer-Kornek5, Astrid Blaschek6, Mareike Schimmel7, Markus Blankenburg8, Matthias Baumann9, Michael Karenfort10, Carsten Finke1, Kevin Rostásy2. 1. Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany. 2. Department of Paediatric Neurology, Children's Hospital Datteln, Witten/Herdecke University, Datteln, Germany. 3. Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany. 4. Department of Paediatric Neurology, Olgahospital, Stuttgart, Germany. 5. Department of Neurology, Medical University of Vienna, Vienna, Austria. 6. Department of Paediatric Neurology and Developmental Medicine, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany. 7. Department of Paediatric Neurology, Children's Hospital Augsburg, Augsburg, Germany. 8. Department of Paediatric Neurology, Children's Hospital Datteln, Witten/Herdecke University, Datteln, Germany/ Department of Paediatric Neurology, Olgahospital, Stuttgart, Germany. 9. Division of Paediatric Neurology, Department of Paediatrics I, Medical University of Innsbruck, Innsbruck, Austria. 10. Department of General Paediatrics, Neonatology and Paediatric Cardiology, University Children's Hospital, Heinrich-Heine-University, Düsseldorf, Germany.
Abstract
BACKGROUND: Paediatric multiple sclerosis (pedMS) patients at a single site were shown to have reduced brain volumes and failure of age-expected brain growth compared to healthy controls. However, the precise time of onset of brain volume loss remains unclear. OBJECTIVE: To longitudinally study brain volumes in a multi-centre European cohort at first presentation and after 2 years. METHODS: Brain volumes of high-resolution magnetic resonance imaging (MRI) data from 37 pedMS patients at first presentation prior to steroid therapy and at 2-year follow-up ( n = 21) were compared to matched longitudinal MRI data from the NIH Paediatric MRI Data Repository. RESULTS: Patients showed significantly reduced whole brain, grey and white matter and increased ventricular volumes at initial presentation and at follow-up compared to controls. Over 2 years, patients exhibited significant reduction of whole brain and white matter volumes, accompanied by increased ventricular volume. Brain volume loss at follow-up correlated with a higher number of infratentorial lesions, relapses and an increased Expanded Disability Status Scale (EDSS) score. CONCLUSIONS: In pedMS patients, brain volume loss is present already at first clinical presentation and accelerated over 2 years. Increased disease activity is associated with more severe brain volume loss. MRI brain volume change might serve as an outcome parameter in future prospective pedMS studies.
BACKGROUND: Paediatric multiple sclerosis (pedMS) patients at a single site were shown to have reduced brain volumes and failure of age-expected brain growth compared to healthy controls. However, the precise time of onset of brain volume loss remains unclear. OBJECTIVE: To longitudinally study brain volumes in a multi-centre European cohort at first presentation and after 2 years. METHODS: Brain volumes of high-resolution magnetic resonance imaging (MRI) data from 37 pedMS patients at first presentation prior to steroid therapy and at 2-year follow-up ( n = 21) were compared to matched longitudinal MRI data from the NIH Paediatric MRI Data Repository. RESULTS:Patients showed significantly reduced whole brain, grey and white matter and increased ventricular volumes at initial presentation and at follow-up compared to controls. Over 2 years, patients exhibited significant reduction of whole brain and white matter volumes, accompanied by increased ventricular volume. Brain volume loss at follow-up correlated with a higher number of infratentorial lesions, relapses and an increased Expanded Disability Status Scale (EDSS) score. CONCLUSIONS: In pedMS patients, brain volume loss is present already at first clinical presentation and accelerated over 2 years. Increased disease activity is associated with more severe brain volume loss. MRI brain volume change might serve as an outcome parameter in future prospective pedMS studies.
Authors: Douglas L Arnold; Brenda Banwell; Amit Bar-Or; Angelo Ghezzi; Benjamin M Greenberg; Emmanuelle Waubant; Gavin Giovannoni; Jerry S Wolinsky; Jutta Gärtner; Kevin Rostásy; Lauren Krupp; Marc Tardieu; Wolfgang Brück; Tracy E Stites; Gregory L Pearce; Dieter A Häring; Martin Merschhemke; Tanuja Chitnis Journal: J Neurol Neurosurg Psychiatry Date: 2020-03-04 Impact factor: 10.154
Authors: Eva Maria Wendel; Helen Sophie Thonke; Annikki Bertolini; Matthias Baumann; Astrid Blaschek; Andreas Merkenschlager; Michael Karenfort; Barbara Kornek; Christian Lechner; Daniela Pohl; Martin Pritsch; Kathrin Schanda; Mareike Schimmel; Charlotte Thiels; Stephan Waltz; Gert Wiegand; Banu Anlar; Nina Barisic; Christian Blank; Markus Breu; Philip Broser; Adela Della Marina; Katharina Diepold; Matthias Eckenweiler; Astrid Eisenkölbl; Michael Freilinger; Ursula Gruber-Sedlmayr; Annette Hackenberg; Tobias Iff; Ellen Knierim; Johannes Koch; Georg Kutschke; Steffen Leiz; Grischa Lischetzki; Margherita Nosadini; Alexander Pschibul; Edith Reiter-Fink; Doris Rohrbach; Michela Salandin; Stefano Sartori; Jan-Ulrich Schlump; Johannes Stoffels; Jurgis Strautmanis; Daniel Tibussek; Victoria Tüngler; Norbert Utzig; Markus Reindl; Kevin Rostásy Journal: Neurol Neuroimmunol Neuroinflamm Date: 2022-10-13
Authors: Stefan J Troche; Tugba Kapanci; Thomas H Rammsayer; Carl P A Kesseler; Martin Georg Häusler; Tobias Geis; Mareike Schimmel; Christiane Elpers; Jonas H Kreth; Charlotte Thiels; Kevin Rostásy Journal: Front Neurol Date: 2020-10-20 Impact factor: 4.003